Natera NTRA

HealthcareMarket cap $60B3 connections

Natera's cell-free DNA technology analyzes DNA fragments floating in blood to detect chromosomal abnormalities before birth (Panorama), cancer recurrence after treatment (Signatera), and organ rejection after transplant (Prospera). 2M+ Panorama prenatal tests have been performed. Liquid biopsy - diagnosing disease from a simple blood draw - is transforming cancer monitoring.

Open Natera's Company Hub Simulate a merger Supply chain See it on the map

Suppliers 2

Companies that sell to Natera

AmazonConsumer & Retail · $2.7TNatera cloud genomics platform on AWS
IlluminaHealthcare · $41BNatera uses Illumina sequencers for genetic tests

Customers 1

Companies Natera sells to

UnitedHealthHealthcare · $338BUnitedHealth covers Natera Panorama prenatal testing

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Natera's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=NTRA" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Natera on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.